SIREN : 402011175
NEXTPHARMA PLOERMEL is a French company founded 30 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in PLOERMEL (56800), this company of category ETI shows in 2024 a revenue of 51.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51 184 985 € | 47 945 554 € | 49 408 032 € | 53 348 169 € | 52 328 582 € | 48 132 943 € | 47 514 054 € | 48 237 076 € | 42 356 810 € |
| Net income | 3 667 976 € | 1 688 926 € | 2 095 708 € | 2 441 998 € | -1 888 769 € | -1 478 556 € | -5 032 330 € | -5 696 483 € | -949 979 € |
| EBITDA | 3 180 056 € | 2 363 347 € | 3 712 305 € | 5 588 436 € | 3 493 654 € | 2 460 982 € | -409 359 € | -2 162 537 € | 572 330 € |
| Net margin | 7.2% | 3.5% | 4.2% | 4.6% | -3.6% | -3.1% | -10.6% | -11.8% | -2.2% |
In 2024, NEXTPHARMA PLOERMEL achieves revenue of 51.2 M€. Revenue is growing positively over 9 years (CAGR: +2.4%). Vs 2023: +7%. After deducting consumption (17.0 M€), gross margin stands at 34.2 M€, i.e. a rate of 67%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.2 M€, representing 6.2% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 3.7 M€, i.e. 7.2% of revenue. This profit can be retained or distributed to shareholders.
51 184 985 €
34 223 979 €
3 180 056 €
1 803 049 €
3 667 976 €
6.2%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 9.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
0.0%
76.713%
9.382%
0.0
30.2%
In 2024, the debt ratio of NEXTPHARMA PLOERMEL (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of NEXTPHARMA PLOERMEL (76.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of NEXTPHARMA PLOERMEL (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 366.06. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.4x. Coverage is limited: any activity downturn would jeopardize interest payments.
366.065
1.428
In 2024, the liquidity ratio of NEXTPHARMA PLOERMEL (366.06) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of NEXTPHARMA PLOERMEL (1.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 72 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 71 days. The company must finance 1 days of gap between collections and payments. Inventory turnover is 86 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 228 days of revenue, i.e. 32.5 M€ to permanently finance. Over 2016-2024, WCR increased by +184%, requiring additional financing.
32 459 982 €
72 j
71 j
86 j
228 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 731 831€ to 2 249 365€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare NEXTPHARMA PLOERMEL with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of NEXTPHARMA PLOERMEL in 2024 is 51.2 M€.
Yes, NEXTPHARMA PLOERMEL generated a net profit of 3.7 M€ in 2024.
The headquarters of NEXTPHARMA PLOERMEL is located in PLOERMEL (56800), in the department Morbihan.
The tax return of NEXTPHARMA PLOERMEL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NEXTPHARMA PLOERMEL operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.